EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - EyePoint Pharmaceuticals reported a revenue of $11.59 million for the quarter ended December 2024, reflecting a decline of 17.4% year-over-year and a significant miss of 21.04% against the Zacks Consensus Estimate of $14.68 million [1] - The company's earnings per share (EPS) was -$0.64, worsening from -$0.33 in the same quarter last year, with a surprise of -56.10% compared to the consensus estimate of -$0.41 [1] Revenue Breakdown - Royalty income was reported at $0.22 million, falling short of the estimated $0.35 million by three analysts, representing a year-over-year decline of 10.4% [4] - Revenue from license and collaboration agreements was $10.59 million, below the average estimate of $13.86 million, marking an 18.7% decrease year-over-year [4] - Product sales, net, reached $0.77 million, slightly exceeding the two-analyst average estimate of $0.70 million, showing a year-over-year increase of 3.3% [4] Stock Performance - Over the past month, shares of EyePoint Pharmaceuticals have decreased by 20.2%, contrasting with a decline of 4.1% in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]